Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study

Area of Science:

• Neuroscience
• Infectious Diseases
• Pharmacology

Background:

• HIV-associated neurocognitive impairment (HAND) affects a significant portion of individuals with HIV.
• Antiretroviral therapy (ART) has improved outcomes but HAND remains a challenge.
• Novel therapeutic strategies are needed to address cognitive deficits in HAND.

Purpose of the Study:

• To evaluate the efficacy and safety of transdermal rivastigmine for treating HAND in patients on stable ART.
• To compare transdermal rivastigmine with lithium and a control group.

Main Methods:

• A randomized controlled pilot trial with 29 HIV-infected patients experiencing cognitive impairment.
• Participants received transdermal rivastigmine, lithium, or no new medication for 48 weeks.
• Primary endpoint: change in global cognitive score (NPZ-7); secondary endpoints: specific cognitive domains and functional parameters.

Main Results:

• No significant differences in the primary cognitive outcome (NPZ-7) were found between groups.
• The rivastigmine group showed a positive trend in NPZ-7 scores (p=0.06).
• Positive trends were noted in information processing speed and executive function, with good tolerability and no severe adverse events.

Conclusions:

• Transdermal rivastigmine did not demonstrate significant cognitive benefits for HAND in this pilot study.
• Emerging positive trends in specific cognitive domains warrant further investigation.
• The treatment was well-tolerated without significant safety concerns.